Session » Epidemiology & Public Health Poster I: RA

Date: Sunday, November 10, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 192

A Healthy Plant-Rich Diet and the Risk of Rheumatoid Arthritis in Women

9:00AM-11:00AM: Abstract Number: 200

A Validated Text-mining Algorithm to Extract Rheumatoid Arthritis Medication Contained in Format-free Fields of Electronic Medical Records

9:00AM-11:00AM: Abstract Number: 185

Accrual of Multimorbidity After Incident Rheumatoid Arthritis and Matched Comparators Using a Large Prospective Cohort with 30 Years of Follow-up

9:00AM-11:00AM: Abstract Number: 190

Accuracy of Administrative Algorithms for Identifying Interstitial Lung Disease in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 198

Assessing Care Quality in Rheumatology Services

9:00AM-11:00AM: Abstract Number: 175

Associations Between Circulating Cytokines and Incident Inflammatory Arthritis in an Anti-citrullinated Protein Antibody Positive Population

9:00AM-11:00AM: Abstract Number: 191

Associations of Self-Reported Inhalant Exposures with Autoantibodies and Disease Severity in U.S. Veterans with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 186

Asthma, Chronic Obstructive Pulmonary Disease, and Subsequent Risk for Incident Rheumatoid Arthritis Among Women: A Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 174

Clinical Presentation and Disease Course Evaluation of Mono- and Bilateral Knee Arthritis: Results from the Leiden Early Arthritis Clinic Cohort

9:00AM-11:00AM: Abstract Number: 182

Comparing the Generalizability of Cardiovascular Risk in Different Rheumatoid Arthritis Cohorts

9:00AM-11:00AM: Abstract Number: 178

Depression: A Common Comorbidity in Rheumatic Diseases. a Case-Control Study

9:00AM-11:00AM: Abstract Number: 193

Diet as a Risk Factor for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 205

Does a Mandatory Non-medical Switch from Originator to Biosimilar Etanercept Lead to Increase in Healthcare Use and Costs? A Danish Register-based Study of 1620 Patients with Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 177

Early Retirement Attributed to Rheumatoid Arthritis and Its Predictors in Portugal

9:00AM-11:00AM: Abstract Number: 207

Effects of Successive Switches to Different Biosimilars Infliximab on Immunogenicity in Chronic Inflammatory Diseases in Daily Clinical Practice

9:00AM-11:00AM: Abstract Number: 206

Efficacy of Etanercept on Radiographic Progression in Adult Patients with Rheumatoid Arthritis or Psoriatic Arthritis: Final Results from a German Non-Interventional, Prospective, Multi-Center Study

9:00AM-11:00AM: Abstract Number: 187

Epidemiology of JIA-Associated Uveitis: Environmental Factors and Disease Characteristics of a JIA-Associated Uveitis Cohort

9:00AM-11:00AM: Abstract Number: 183

Exploring Heterogeneity in Rheumatoid Arthritis: Patient Profiling Through Principal Component and Cluster Analysis of the BRASS Registry

9:00AM-11:00AM: Abstract Number: 201

Identification of Patients with Rheumatoid Arthritis Treated with Biologics Using Standardized Vocabularies

9:00AM-11:00AM: Abstract Number: 180

Identifying Comorbidities and Seropositivity in Rheumatoid Arthritis Patients Using Single-specialty Electronic Health Record Data

9:00AM-11:00AM: Abstract Number: 172

Is the Epidemiology of Rheumatoid Arthritis (RA) Changing? Results from a Population-based Incidence Cohort of RA Patients, 2005-2014

9:00AM-11:00AM: Abstract Number: 184

No Increased Risk of Incidence Diabetes in Patients with Rheumatoid Arthritis Compared to Patients Without RA

9:00AM-11:00AM: Abstract Number: 199

Obesity and Incident Opioid Use in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 171

Performance of 2010 ACR/EULAR and 1987 ACR Criteria for Classification of Rheumatoid Arthritis in a Population-based Incidence Cohort, 2010-2014

9:00AM-11:00AM: Abstract Number: 194

Predicting Remission in Rheumatoid Arthritis: External Validation for Tocilizumab Monotherapy Using Corrona Real World Data

9:00AM-11:00AM: Abstract Number: 181

Prevalence of Renal Impairment in a US Rheumatoid Arthritis Population

9:00AM-11:00AM: Abstract Number: 204

Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US

9:00AM-11:00AM: Abstract Number: 203

Recent Use, Missed Doses and Discontinuation of Infliximab in a Population-Based Cohort: Comparisons of Biosimilar and Originator Exposures

9:00AM-11:00AM: Abstract Number: 202

Risk Factors Associated with Serious Infections Among Users of Biosimilar and Originator Infliximab Therapies

9:00AM-11:00AM: Abstract Number: 196

Risk of Subsequent Atherosclerotic Cardiovascular Disease After the First Unprovoked Venous Thromboembolism in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 173

Statin Use Is Associated with Increased Risk of RA in US Population: Results from a Large Nationwide Study

9:00AM-11:00AM: Abstract Number: 179

The Burden of Comorbidity in Patients with RA, PSA or SPA in a General Practice Registry

9:00AM-11:00AM: Abstract Number: 195

The Clinical Characteristics of Patients with Inflammatory Arthritis and a Persistently Low Alkaline Phosphatase Level in a Veteran Affairs Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 176

The Epidemiology of Rheumatoid Arthritis in the Czech Republic

9:00AM-11:00AM: Abstract Number: 188

The Importance of Diagnosis: Clinical Distinctions Between Adult JIA and RA, and a Characterization of Patients with JIA Reclassified as RA in Adulthood

9:00AM-11:00AM: Abstract Number: 197

The Relationship Between Pain and Patient Demographics, Clinical Features, and Health Outcomes in a Cohort of Rheumatoid Arthritis Patients Recruited and Studied Using a Mobile Application

9:00AM-11:00AM: Abstract Number: 189

Validation of Claims-based Algorithms to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].